Improved sleep correlates with improved quality of life and motor symptoms with foslevodopa/foscarbidopa
No Thumbnail Available
Authors
Chaudhuri, K. Ray
Facheris, Maurizio F.
Bergmans, Bruno
Bergquist, Filip
Criswell, Susan R.
Jia, Jia
Kukreja, Pavnit
Mukai, Yohei
Spiegel, Amy M.
Gupta, Resmi
Check for full-text access
Issue Date
2024
Type
Article
Language
Keywords
Alternative Title
Abstract
BACKGROUND: Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs. OBJECTIVES: Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167). METHODS: Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and "Off"/"On" times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score. RESULTS: Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved "Off" time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, "Off" time, QoL, and m-EDL. CONCLUSIONS: Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and "Off" time.
Description
Citation
Publisher
License
Journal
Movement Disorders Clinical Practice
Volume
11
Issue
7